{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T03:01:30Z","timestamp":1763348490843},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00292-022-01108-x","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T12:03:17Z","timestamp":1662984197000},"page":"25-30","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["IL-2\/IL-2R signaling and IL-2R\u03b1-targeted therapy in anaplastic large cell lymphoma","IL-2\/IL-2R-Signal\u00fcbertragung und gezielte IL-2R\u03b1-Therapie bei anaplastischem gro\u00dfzelligem Lymphom"],"prefix":"10.1007","volume":"43","author":[{"given":"Huan-Chang","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"1108_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose\u00a0J, Armitage\u00a0J, Weisenburger\u00a0D et al (2008) International peripheral T\u2011cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J\u00a0Clin Oncol 26:4124\u20134130","journal-title":"J Clin Oncol"},{"key":"1108_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1200\/JCO.1991.9.4.539","volume":"9","author":"J Greer","year":"1991","unstructured":"Greer\u00a0J, Kinney\u00a0M, Collins\u00a0R et al (1991) Clinical features of 31\u00a0patients with Ki\u20111 anaplastic large-cell lymphoma. J\u00a0Clin Oncol 9:539\u2013547","journal-title":"J Clin Oncol"},{"key":"1108_CR3","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"S Swerdlow","year":"2017","unstructured":"Swerdlow\u00a0S, Campo\u00a0E, Harris\u00a0N et\u00a0al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th\u00a0edn. World Health Organization, Geneva","edition":"4"},{"key":"1108_CR4","doi-asserted-by":"publisher","first-page":"E93","DOI":"10.3390\/cancers10040093","volume":"10","author":"HC Liang","year":"2018","unstructured":"Garces de los Fayos Alonso I, Liang\u00a0HC, Turner\u00a0SD et al (2018) The role of activator protein\u20111 (AP-1) family members in CD30-positive lymphomas. Cancers (Basel) 10:E93","journal-title":"Cancers (Basel)"},{"key":"1108_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","volume":"27","author":"R Crescenzo","year":"2015","unstructured":"Crescenzo\u00a0R, Abate\u00a0F, Lasorsa\u00a0E et\u00a0al (2015) Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 27:516\u2013532","journal-title":"Cancer Cell"},{"key":"1108_CR6","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1182\/blood-2012-01-405555","volume":"120","author":"L Agnelli","year":"2012","unstructured":"Agnelli\u00a0L, Mereu\u00a0E, Pellegrino\u00a0E et al (2012) Identification of a\u00a03-gene model as a\u00a0powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood 120:1274\u20131281","journal-title":"Blood"},{"key":"1108_CR7","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41375-018-0045-9","volume":"32","author":"N Schleussner","year":"2018","unstructured":"Schleussner\u00a0N, Merkel\u00a0O, Costanza\u00a0M et al (2018) The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17\/ILC3 skewing of anaplastic large cell lymphoma. Leukemia 32:1994\u20132007","journal-title":"Leukemia"},{"key":"1108_CR8","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1038\/s41467-021-25379-9","volume":"12","author":"HC Liang","year":"2021","unstructured":"Liang\u00a0HC, Costanza\u00a0M, Prutsch\u00a0N et al (2021) Super-enhancer-based identification of a\u00a0BATF3\/IL-2R\u2212module reveals vulnerabilities in anaplastic large cell lymphoma. Nat Commun 12:5577","journal-title":"Nat Commun"},{"key":"1108_CR9","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1073\/pnas.1700682114","volume":"114","author":"J Chen","year":"2017","unstructured":"Chen\u00a0J, Zhang\u00a0Y, Petrus\u00a0MN et al (2017) Cytokine receptor signaling is required for the survival of ALK-anaplastic large cell lymphoma, even in the presence of JAK1\/STAT3 mutations. Proc Natl Acad Sci USA 114:3975\u20133980","journal-title":"Proc Natl Acad Sci USA"},{"key":"1108_CR10","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1182\/blood-2006-06-028969","volume":"109","author":"L Lamant","year":"2007","unstructured":"Lamant\u00a0L, de Reyni\u00e8s\u00a0A, Duplantier\u00a0M et al (2007) Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 109:2156\u20132164","journal-title":"Blood"},{"key":"1108_CR11","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","volume":"115","author":"J Iqbal","year":"2010","unstructured":"Iqbal\u00a0J, Weisenburger\u00a0DD, Greiner\u00a0TC et al (2010) Molecular signatures to improve diagnosis in peripheral T\u2011cell lymphoma and prognostication in angioimmunoblastic T\u2011cell lymphoma. Blood 115:1026\u20131036","journal-title":"Blood"},{"key":"1108_CR12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/S0002-9440(10)65667-2","volume":"153","author":"ML Boulland","year":"1998","unstructured":"Boulland\u00a0ML, Meignin\u00a0V, Leroy-Viard\u00a0K et al (1998) Human interleukin-10 expression in T\/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas. Am J Pathol 153:1229\u20131237","journal-title":"Am J Pathol"},{"key":"1108_CR13","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1038\/leu.2008.129","volume":"22","author":"DJ Bard","year":"2008","unstructured":"Bard\u00a0DJ, Gelebart\u00a0P, Anand\u00a0M et al (2008) Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia 22:1595\u20131603","journal-title":"Leukemia"},{"key":"1108_CR14","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41375-018-0239-1","volume":"33","author":"N Prutsch","year":"2019","unstructured":"Prutsch\u00a0N, Gurnhofer\u00a0E, Suske\u00a0T et\u00a0al (2019) Dependency on the TYK2\/STAT1\/MCL1 axis in anaplastic large cell lymphoma. Leukemia 33:696\u2013709","journal-title":"Leukemia"},{"key":"1108_CR15","first-page":"1657","volume":"136","author":"N Prokoph","year":"2020","unstructured":"Prokoph\u00a0N, Probst\u00a0N, Lee\u00a0L et al (2020) IL10RA modulates crizotinib sensitivity in NPM1-ALK-positive anaplastic large cell lymphoma. Blood 136:1657\u20131669","journal-title":"Blood"},{"key":"1108_CR16","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3324\/haematol.2013.085068","volume":"98","author":"L Couronn\u00e9","year":"2013","unstructured":"Couronn\u00e9\u00a0L, Scourzic\u00a0L, Pilati\u00a0C et\u00a0al (2013) STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a\u00a0mouse bone marrow transplantation model. Haematologica 98:1748\u20131752","journal-title":"Haematologica"},{"key":"1108_CR17","doi-asserted-by":"publisher","first-page":"34201","DOI":"10.18632\/oncotarget.9077","volume":"7","author":"S Ehrentraut","year":"2016","unstructured":"Ehrentraut\u00a0S, Schneider\u00a0B, Nagel\u00a0S et al (2016) Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a\u00a0cutaneous T\u2011cell lymphoma. Oncotarget 7:34201\u201334216","journal-title":"Oncotarget"},{"key":"1108_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41586-018-0830-7","volume":"565","author":"DA Silva","year":"2019","unstructured":"Silva\u00a0DA, Yu\u00a0S, Ulge\u00a0UY et al (2019) De novo design of potent and selective mimics of IL\u20112 and IL-15. Nature 565:186\u2013191","journal-title":"Nature"},{"key":"1108_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1158\/2326-6066.CIR-15-0009","volume":"3","author":"TA Waldmann","year":"2015","unstructured":"Waldmann\u00a0TA (2015) The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res 3:219\u2013227","journal-title":"Cancer Immunol Res"},{"key":"1108_CR20","doi-asserted-by":"publisher","first-page":"11977","DOI":"10.1073\/pnas.1100319108","volume":"108","author":"Q Zhang","year":"2011","unstructured":"Zhang\u00a0Q, Wang\u00a0HY, Liu\u00a0X et al (2011) IL-2R common \u03b3\u2011chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a\u00a0tumor suppressor by targeting NPM-ALK. Proc Natl Acad Sci USA 108:11977\u201311982","journal-title":"Proc Natl Acad Sci USA"},{"key":"1108_CR21","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/leu.2016.292","volume":"31","author":"E Pomari","year":"2017","unstructured":"Pomari\u00a0E, Basso\u00a0G, Bresolin\u00a0S et al (2017) NPM-ALK expression levels identify two distinct subtypes of paediatric anaplastic large cell lymphoma. Leukemia 31:498\u2013501","journal-title":"Leukemia"},{"key":"1108_CR22","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1002\/eji.200737772","volume":"37","author":"CA Dinarello","year":"2007","unstructured":"Dinarello\u00a0CA (2007) Historical review of cytokines. Eur J Immunol 37:S34\u2013S45","journal-title":"Eur J Immunol"},{"key":"1108_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","volume":"38","author":"W Liao","year":"2013","unstructured":"Liao\u00a0W, Lin\u00a0J\u2011X, Leonard\u00a0WJ (2013) Interleukin-2\u202fat the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38:13\u201325","journal-title":"Immunity"},{"key":"1108_CR24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nri2818","volume":"10","author":"MR M\u00fcller","year":"2010","unstructured":"M\u00fcller\u00a0MR, Rao\u00a0A (2010) NFAT, immunity and cancer: a\u00a0transcription factor comes of age. Nat Rev Immunol 10:645\u2013656","journal-title":"Nat Rev Immunol"},{"key":"1108_CR25","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1158\/1078-0432.CCR-12-0101","volume":"18","author":"MG Lechner","year":"2012","unstructured":"Lechner\u00a0MG, Megiel\u00a0C, Church\u00a0CH et al (2012) Survival signals and targets for therapy in breast implant-associated ALK-anaplastic large cell lymphoma. Clin Cancer Res 18:4549\u20134559","journal-title":"Clin Cancer Res"},{"key":"1108_CR26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.59566\/IJBS.2011.7181","volume":"7","author":"M Ito","year":"2011","unstructured":"Ito\u00a0M, Zhao\u00a0N, Zeng\u00a0Z et al (2011) Interleukin\u20112 functions in anaplastic large cell lymphoma cells through augmentation of extracellular signal-regulated kinases 1\/2 activation. Int J Biomed Sci 7:181\u2013190","journal-title":"Int J Biomed Sci"},{"key":"1108_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3324\/haematol.2017.177972","volume":"103","author":"F Kn\u00f6rr","year":"2018","unstructured":"Kn\u00f6rr\u00a0F, Damm-Welk\u00a0C, Ruf\u00a0S et al (2018) Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Haematologica 103:477\u2013485","journal-title":"Haematologica"},{"key":"1108_CR28","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1359-6101(02)00029-1","volume":"13","author":"JP Lodolce","year":"2002","unstructured":"Lodolce\u00a0JP, Burkett\u00a0PR, Koka\u00a0RM et al (2002) Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev 13:429\u2013439","journal-title":"Cytokine Growth Factor Rev"},{"key":"1108_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood.V97.1.14","volume":"97","author":"TA Fehniger","year":"2001","unstructured":"Fehniger\u00a0TA, Caligiuri\u00a0MA (2001) Interleukin 15: biology and relevance to human disease. Blood 97:14\u201332","journal-title":"Blood"},{"key":"1108_CR30","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/leu.2014.345","volume":"29","author":"K Ullrich","year":"2015","unstructured":"Ullrich\u00a0K, Blumenthal-Barby\u00a0F, Lamprecht\u00a0B et al (2015) The IL-15 cytokine system provides growth and survival signals in Hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells. Leukemia 29:1213\u20131218","journal-title":"Leukemia"},{"key":"1108_CR31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1200\/JCO.2008.18.1487","volume":"27","author":"L Brugi\u00e8res","year":"2009","unstructured":"Brugi\u00e8res\u00a0L, Le Deley\u00a0MC, Rosolen\u00a0A et al (2009) Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a\u00a0randomized trial of the EICNHL group. J\u00a0Clin Oncol 27:897\u2013903","journal-title":"J Clin Oncol"},{"key":"1108_CR32","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/pbc.22940","volume":"56","author":"G Wrobel","year":"2011","unstructured":"Wrobel\u00a0G, Mauguen\u00a0A, Rosolen\u00a0A et\u00a0al (2011) Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial. Pediatr Blood Cancer 56:1071\u20131077","journal-title":"Pediatr Blood Cancer"},{"key":"1108_CR33","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes\u00a0A, Bartlett\u00a0NL, Leonard\u00a0JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N\u00a0Engl J Med 363:1812\u20131821","journal-title":"N Engl J Med"},{"key":"1108_CR34","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood.V124.21.3095.3095","volume":"124","author":"B Pro","year":"2014","unstructured":"Pro\u00a0B, Advani\u00a0R, Brice\u00a0P et al (2014) Four-year survival data from an ongoing pivotal phase 2\u00a0study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 124:3095","journal-title":"Blood"},{"key":"1108_CR35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1634\/theoncologist.2019-0098","volume":"24","author":"N Richardson","year":"2019","unstructured":"Richardson\u00a0N, Kasamon\u00a0Y, Chen\u00a0H et al (2019) FDA approval summary: brentuximab vedotin in first-line treatment of peripheral T\u2011cell lymphoma. Oncologist 24:180\u2013187","journal-title":"Oncologist"},{"key":"1108_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz\u00a0S, O\u2019Connor\u00a0OA, Pro\u00a0B et al (2019) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T\u2011cell lymphoma (ECHELON-2): a\u00a0global, double-blind, randomised, phase 3 trial. Lancet 393:229\u2013240","journal-title":"Lancet"},{"key":"1108_CR37","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/01.cji.0000175468.19742.10","volume":"28","author":"P Attia","year":"2005","unstructured":"Attia\u00a0P, Maker\u00a0AV, Haworth\u00a0LR et al (2005) Inability of a\u00a0fusion protein of IL\u20112 and diphtheria toxin (denileukin diftitox, DAB389IL\u20112, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J\u00a0Immunother 28:582\u2013592","journal-title":"J Immunother"},{"key":"1108_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/CMAR.S5009","volume":"2","author":"F Lansigan","year":"2010","unstructured":"Lansigan\u00a0F, Stearns\u00a0DM, Foss\u00a0F (2010) Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T\u2011cell lymphoma. Cancer Manag Res 2:53\u201359","journal-title":"Cancer Manag Res"},{"key":"1108_CR39","first-page":"399","volume":"91","author":"CF LeMaistre","year":"1998","unstructured":"LeMaistre\u00a0CF, Saleh\u00a0MN, Kuzel\u00a0TM et al (1998) Phase I trial of a\u00a0ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin\u20112. Blood 91:399\u2013405","journal-title":"Blood"},{"key":"1108_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/(SICI)1096-8652(199805)58:1<87::AID-AJH18>3.0.CO;2-2","volume":"58","author":"M Duvic","year":"1998","unstructured":"Duvic\u00a0M, Cather\u00a0J, Maize\u00a0J, Frankel\u00a0AE (1998) DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T\u2011cell lymphoma. Am J Hematol 58:87\u201390","journal-title":"Am J Hematol"},{"key":"1108_CR41","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","volume":"28","author":"HM Prince","year":"2010","unstructured":"Prince\u00a0HM, Duvic\u00a0M, Martin\u00a0A et al (2010) Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T\u2011cell lymphoma. J\u00a0Clin Oncol 28:1870\u20131877","journal-title":"J Clin Oncol"},{"key":"1108_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jim.2017.05.008","volume":"448","author":"Z Wang","year":"2017","unstructured":"Wang\u00a0Z, Zheng\u00a0Q, Zhang\u00a0H et al (2017) Ontak-like human IL\u20112 fusion toxin. J\u00a0Immunol Methods 448:51\u201358","journal-title":"J Immunol Methods"},{"key":"1108_CR43","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","volume":"15","author":"MJ Flynn","year":"2016","unstructured":"Flynn\u00a0MJ, Zammarchi\u00a0F, Tyrer\u00a0PC et al (2016) ADCT-301, a\u00a0pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies. Mol Cancer Ther 15:2709\u20132721","journal-title":"Mol Cancer Ther"}],"container-title":["Die Pathologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-022-01108-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-022-01108-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-022-01108-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T21:12:15Z","timestamp":1701033135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-022-01108-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":43,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1108"],"URL":"https:\/\/doi.org\/10.1007\/s00292-022-01108-x","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"22 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.\u2011C.\u00a0Liang declares that he has no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}